Motley Fool Money cover image

Customers for Life?

Motley Fool Money

00:00

Intro

This chapter examines the effects of the weight loss drugs ZepBound and Munjaro on various industries, with a particular focus on the medtech sector. It highlights ResMed's stock decline related to sleep apnea treatment and discusses the broader implications for markets and investors.

Play episode from 00:00
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app